



## Clinical trial results:

### An Open-Label Extension Study Of The Safety And Clinical Utility Of IPX203 In Parkinson's Disease Patients With Motor Fluctuations

#### Summary

EudraCT number	2018-002234-21
Trial protocol	DE CZ ES GB PL IT
Global end of trial date	21 March 2022

#### Results information

Result version number	v1 (current)
This version publication date	01 July 2023
First version publication date	01 July 2023

#### Trial information

##### Trial identification

Sponsor protocol code	IPX203-B16-03
-----------------------	---------------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT03877510
WHO universal trial number (UTN)	-

Notes:

#### Sponsors

Sponsor organisation name	Impax Laboratories, LLC
Sponsor organisation address	400 Crossing Boulevard, Third Floor, Bridgewater, NJ, United States, 08807
Public contact	Pamela Fitzpatrick, Impax Laboratories, LLC, +1 631-633-2104, pfitzpatrick@amneal.com
Scientific contact	Pamela Fitzpatrick, Impax Laboratories, LLC, +1 631-633-2104, pfitzpatrick@amneal.com

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	21 March 2022
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	21 March 2022
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

To evaluate the long-term safety and clinical utility of IPX203 in the treatment of subjects with advanced Parkinson's disease (PD) who have motor fluctuations.

Protection of trial subjects:

This study was conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki and that are consistent with the International Conference on Harmonization (ICH) guidelines for Good Clinical Practice (GCP) and applicable regulatory requirements.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	03 April 2019
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	United States: 209
Country: Number of subjects enrolled	Czechia: 28
Country: Number of subjects enrolled	France: 10
Country: Number of subjects enrolled	Germany: 30
Country: Number of subjects enrolled	Italy: 27
Country: Number of subjects enrolled	Poland: 66
Country: Number of subjects enrolled	Spain: 39
Country: Number of subjects enrolled	United Kingdom: 10
Worldwide total number of subjects	419
EEA total number of subjects	200

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0

Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	152
From 65 to 84 years	264
85 years and over	3

## Subject disposition

### Recruitment

Recruitment details:

Subjects took part in the study at 94 sites across the United States, Italy, Spain, France, United Kingdom, Czech Republic, Poland, and Germany.

### Pre-assignment

Screening details:

The study IPX203-B16-03 was a 9-month, open-label extension of study IPX203-B16-02. Subjects who had successfully completed Study IPX203-B16-02 had opportunity to enroll in this open-label study. A total of 419 subjects enrolled from study IPX203-B16-02, 206 subjects from the previous IPX203 group and 213 subjects from the previous IR-CD-LD group.

### Period 1

Period 1 title	Overall (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

### Arms

Arm title	IPX203
-----------	--------

Arm description:

IPX203 carbidopa-levodopa (CD-LD) extended-release (ER) capsules, orally in 4 different dose strength (35-140 mg, 52.5-210 mg, 70-280 mg, 87.5-350 mg) as per Investigator's discretion.

Arm type	Experimental
Investigational medicinal product name	IPX203 CD-LD ER Capsules
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

IPX203 (carbidopa-levodopa) ER capsules orally in 4 different dose strength (35-140 mg, 52.5-210 mg, 70-280 mg, 87.5-350 mg) as per Investigator's discretion.

<b>Number of subjects in period 1</b>	IPX203
Started	419
Completed	352
Not completed	67
Consent withdrawn by subject	22
Adverse event, non-fatal	20
Death	6
Other	1
Non-compliance with study drug	2
Lost to follow-up	2
Lack of efficacy	14



## Baseline characteristics

### Reporting groups

Reporting group title	IPX203
-----------------------	--------

Reporting group description:

IPX203 carbidopa-levodopa (CD-LD) extended-release (ER) capsules, orally in 4 different dose strength (35-140 mg, 52.5-210 mg, 70-280 mg, 87.5-350 mg) as per Investigator's discretion.

Reporting group values	IPX203	Total	
Number of subjects	419	419	
Age categorical			
Units: Subjects			
Age continuous			
Units: years			
arithmetic mean	66.9		
standard deviation	± 8.86	-	
Gender categorical			
Units: Subjects			
Female	140	140	
Male	279	279	
Race			
Units: Subjects			
Asian	6	6	
Black or African American	4	4	
White	406	406	
Unknown or not reported	3	3	
Ethnicity			
Units: Subjects			
Not Hispanic or Latino	369	369	
Hispanic or Latino	46	46	
Not reported	4	4	

## End points

### End points reporting groups

Reporting group title	IPX203
Reporting group description: IPX203 carbidopa-levodopa (CD-LD) extended-release (ER) capsules, orally in 4 different dose strength (35-140 mg, 52.5-210 mg, 70-280 mg, 87.5-350 mg) as per Investigator's discretion.	

### Primary: Number of Subjects with Treatment-emergent Adverse Events (TEAEs)

End point title	Number of Subjects with Treatment-emergent Adverse Events (TEAEs) <sup>[1]</sup>
-----------------	--

End point description:

An AE was defined as any untoward medical occurrence in a subject or clinical trial subject administered a medicinal product and which did not necessarily have to have a causal relationship with the treatment. An AE could therefore be any unfavorable and unintended sign (example, an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A TEAE was defined as an adverse event with an onset that occurs after receiving study drug. The safety analysis set included all subjects who were treated with the open-label study drug in the study.

End point type	Primary
----------------	---------

End point timeframe:

From first dose up to 1 day after last dose (Up to 9 months/Early Termination [ET])

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Planned analyses for these data was descriptive only.

<b>End point values</b>	IPX203			
Subject group type	Reporting group			
Number of subjects analysed	419			
Units: subjects	221			

### Statistical analyses

No statistical analyses for this end point

### Secondary: Movement Disorders Society Version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Part I Score

End point title	Movement Disorders Society Version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Part I Score
-----------------	--

End point description:

MDS-UPDRS was a multimodal scale assessing impairment and disability. Measure of the MDS-UPDRS - Part I: Non-Motor Aspects of Experiences of Daily Living (nM-EDL) has 2 components. Component IA contains a number of behaviors assessed by the investigator with all pertinent information from the subject and caregivers. Component IB is completed by the subject with or without help from the caregiver but independent of the investigator. Overall, there are 13 questions rated from 0 - normal to 4- severe. Total score ranges from 0 to 52. with higher scores reflecting greater severity. The Intent-to-treat analysis set (ITT) included all subjects who were treated with the open-label study drug in the study and have at least one post-baseline clinical utility assessment. Here overall number analyzed "N"

are the subjects who were evaluable for the outcome measure and "n" signifies subjects who were evaluable for each specified category. ET stands for early termination.

End point type	Secondary
End point timeframe:	
Baseline, Month 3, Month 6 and Month 9	

End point values	IPX203			
Subject group type	Reporting group			
Number of subjects analysed	410			
Units: score on a scale				
arithmetic mean (standard deviation)				
Baseline (n=410)	9.9 (± 6.27)			
Month 3 (n=390)	10.6 (± 6.43)			
Month 6 (n=362)	10.7 (± 6.21)			
Month 9/ET (n=393)	11.0 (± 6.72)			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Movement Disorders Society Version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Part IV Score

End point title	Movement Disorders Society Version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Part IV Score
-----------------	---

End point description:

Part 4 of the MDS-UPDRS objectively measures the disability associated with levodopa-induced dyskinesia. Disability was assessed via video analysis by unbiased blinded central raters. Disability was evaluated for communication, drinking from a cup, and ambulation items. 6 questions rated from 0 - normal to 4 severe. Total score ranges from 0 to 24. A higher score indicated more severe symptoms. The ITT set included all subjects who were treated with the open-label study drug in the study and have at least one post-baseline clinical utility assessment. Here overall number analyzed "N" are the subjects who were evaluable for the outcome measure and "n" signifies subjects who were evaluable for each specified category.

End point type	Secondary
End point timeframe:	
Baseline, Month 3, Month 6 and Month 9	

End point values	IPX203			
Subject group type	Reporting group			
Number of subjects analysed	410			
Units: score on a scale				
arithmetic mean (standard deviation)				
Baseline (n=410)	6.6 (± 2.96)			
Month 3 (n=382)	6.0 (± 3.15)			
Month 6 (n=358)	6.0 (± 3.08)			
Month 9/ET (n=393)	6.6 (± 3.34)			



## Statistical analyses

No statistical analyses for this end point

### Secondary: Movement Disorders Society Version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Part II Score

End point title	Movement Disorders Society Version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Part II Score
-----------------	---

End point description:

Measure of the MDS-UPDRS - Part II: Motor Aspects of Experiences of Daily Living (M-EDL) was a self-administered questionnaire overall there are 13 questions rated from 0 - normal to 4 severe. Total score ranges from 0 to 52., with a lower score indicating better motor function for daily living and higher score indicating more severe motor symptoms. The ITT included all subjects who were treated with the open-label study drug in the study and have at least one post-baseline clinical utility assessment. Here overall number analyzed "N" are the subjects who were evaluable for the outcome measure and "n" signifies subjects who were evaluable for each specified category.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Month 3, Month 6 and Month 9

End point values	IPX203			
Subject group type	Reporting group			
Number of subjects analysed	409			
Units: score on a scale				
arithmetic mean (standard deviation)				
Baseline (n=409)	12.8 (± 7.83)			
Month 3 (n=390)	13.0 (± 7.96)			
Month 6 (n=362)	12.8 (± 7.69)			
Month 9/ET (n=393)	13.6 (± 8.11)			

## Statistical analyses

No statistical analyses for this end point

### Secondary: Movement Disorders Society version of the Unified Parkinson's disease Rating Scale (MDS-UPDRS): Sums of Part II and Part III Score

End point title	Movement Disorders Society version of the Unified Parkinson's disease Rating Scale (MDS-UPDRS): Sums of Part II and Part III Score
-----------------	--

End point description:

Sum of MDS-UPDRS Parts II and III. Part II: Motor Aspects of Experiences of Daily Living (M-EDL) self-administered questionnaire. 13 questions rated from 0 - normal to 4 severe. Total score ranges from 0 to 52. Part III: Motor Examination assesses the motor signs of PD; completed by the rater. 33 questions

rated from 0 normal to 4 severe. Total score ranges from 0 to 132. Total score ranges from 0 (no symptom) to 184 (severe symptoms), higher score indicated more severe symptoms. The ITT set included all subjects who were treated with the open-label study drug in the study and have at least one post-baseline clinical utility assessment. Here overall number analyzed "N" are the subjects who were evaluable for the outcome measure and "n" signifies subjects who were evaluable for each specified category.

End point type	Secondary
End point timeframe:	
Baseline, Month 3, Month 6, and Month 9	

<b>End point values</b>	IPX203			
Subject group type	Reporting group			
Number of subjects analysed	409			
Units: score on scale				
arithmetic mean (standard deviation)				
Baseline (n=409)	40.3 (± 23.09)			
Month 3 (n=379)	39.8 (± 24.15)			
Month 6 (n=356)	39.4 (± 23.24)			
Month 9/ET (n=393)	41.5 (± 22.96)			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Movement Disorders Society Version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Part III Score

End point title	Movement Disorders Society Version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Part III Score
-----------------	--

End point description:

Measure of the MDS-UPDRS - Part III: Motor Examination assesses the motor signs of PD; it is completed by the rater. 33 questions rated from 0 - normal to 4 severe. Total score ranges from 0 to 132, with a lower score indicating better motor function and a higher score indicating more severe motor symptoms. The ITT set included all subjects who were treated with the open-label study drug in the study and have at least one post-baseline clinical utility assessment. Here overall number analyzed "N" are the subjects who were evaluable for the outcome measure and "n" signifies subjects who were evaluable for each specified category.

End point type	Secondary
End point timeframe:	
Baseline, Month 3, Month 6, and Month 9	

<b>End point values</b>	IPX203			
Subject group type	Reporting group			
Number of subjects analysed	410			
Units: score on a scale				
arithmetic mean (standard deviation)				
Baseline (n=410)	27.5 (± 17.23)			

Month 3 (n=379)	26.8 (± 17.90)			
Month 6 (n=357)	26.6 (± 17.50)			
Month 9/ET (n=393)	27.8 (± 16.79)			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Movement Disorders Society Version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Total Score

End point title	Movement Disorders Society Version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Total Score
End point description:	
Measure of MDS-UPDRS - sum total of 4 parts.Part I: Non-Motor Aspects of Experiences of Daily Living (nM-EDL) has 2 components.Component IA contains a number of behaviors assessed by investigator.Component IB is completed by subject.Overall, there are 13 questions rated from 0 normal to 4 severe.Total score ranges from 0 to 52, higher score more severe symptoms.Part II: Motor Aspects of Experiences of Daily Living (M-EDL) self-administered questionnaire.13 questions rated from 0 normal to 4 severe.Total score ranges from 0 to 52. Part III: Motor Examination assesses motor signs of PD; completed by rater. 33 questions rated from 0 normal to 4 severe.Total score ranges 0 to 132 Part IV: Motor Complications; completed by rater. 6 questions rated from 0 normal to 4 severe.Total score ranges from 0 to 24.Overall sum ranges from 0-260. ITT set was used.Here "N" are subjects who were evaluable for outcome measure; "n" signifies subjects who were evaluable for each specified category.	
End point type	Secondary
End point timeframe:	
Baseline, Month 3, Month 6 and Month 9	

<b>End point values</b>	IPX203			
Subject group type	Reporting group			
Number of subjects analysed	409			
Units: score on a scale				
arithmetic mean (standard deviation)				
Baseline (n=409)	56.7 (± 28.64)			
Month 3 (n=379)	56.5 (± 30.14)			
Month 6 (n=355)	56.0 (± 28.92)			
Month 9/ET (n=393)	59.0 (± 29.11)			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Patient Global Impression of Severity (PGI-S) Score

End point title	Patient Global Impression of Severity (PGI-S) Score
End point description:	
The PGI-S was a subject answered assessment rating Parkinson's disease severity on a scale of 1 to 7; 1 being normal not at all ill and 7 extremely severely ill. Higher value indicates increased improvement. The ITT set included all subjects who were treated with the open-label study drug in the study and have	

at least one post-baseline clinical utility assessment. Here overall number analyzed "N" are the subjects who were evaluable for the outcome measure and "n" signifies subjects who were evaluable for each specified category.

End point type	Secondary
End point timeframe:	
Baseline, Month 3, Month 6 and Month 9	

<b>End point values</b>	IPX203			
Subject group type	Reporting group			
Number of subjects analysed	409			
Units: score on a scale				
arithmetic mean (standard deviation)				
Baseline (n=409)	3.7 (± 1.02)			
Month 3 (n=390)	3.8 (± 1.00)			
Month 6 (n=363)	3.7 (± 0.99)			
Month 9/ET (n=393)	3.8 (± 1.12)			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Clinical Global Impression of Severity (CGI-S) Score

End point title	Clinical Global Impression of Severity (CGI-S) Score
End point description:	
<p>The CGI-I was intended as a measure of change in health status. CGI-I scores ranged from 1 (very much improved) through to 7 (very much worse). For the CGI-I, subjects were divided into one of two groups, Responders or Progressors. Responders were scored on a scale of 1-4 which was rated as "no change", "minimally improved", "much improved" or "very much improved." Progressors were scored on a scale of 5-7 which was rated as "minimally worse", "much worse" or "very much worse." The ITT set included all subjects who were treated with the open-label study drug in the study and have at least one post-baseline clinical utility assessment. Here overall number analyzed "N" are the subjects who were evaluable for the outcome measure and "n" signifies subjects who were evaluable for each specified category.</p>	
End point type	Secondary
End point timeframe:	
Baseline, Month 3, Month 6 and Month 9	

<b>End point values</b>	IPX203			
Subject group type	Reporting group			
Number of subjects analysed	409			
Units: score on a scale				
arithmetic mean (standard deviation)				
Baseline (n=409)	3.8 (± 0.87)			
Month 3 (n=383)	3.8 (± 0.92)			
Month 6 (n=358)	3.7 (± 0.87)			
Month 9/ET (n=392)	3.8 (± 0.97)			

## Statistical analyses

No statistical analyses for this end point

### Secondary: 39-item Parkinson's Disease Questionnaire (PDQ-39) Total Score

End point title	39-item Parkinson's Disease Questionnaire (PDQ-39) Total Score
-----------------	--

End point description:

The PDQ-39 was a disease-specific instrument designed to measure aspects of health that were relevant to subjects with PD, and which may not be included in general health status questionnaires. It evaluated the 8 domains using 39-items of mobility, activities of daily living, emotional well-being, stigma, social support, cognition, communication and bodily discomfort. Total scores were calculated for the entire questionnaire and each domain. The full range of the PDQ-39 Summary Index score is from 0 (no subject-related symptoms/quality of life unaffected) to 100 (highest subject-related symptoms/low quality of life). The ITT set included all subjects who were treated with the open-label study drug in the study and have at least one post-baseline clinical utility assessment. Here overall number analyzed "N" are the subjects who were evaluable for the outcome measure and "n" signifies subjects who were evaluable for each specified category.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Month 3, Month 6 and Month 9

End point values	IPX203			
Subject group type	Reporting group			
Number of subjects analysed	406			
Units: score on a scale				
arithmetic mean (standard deviation)				
Baseline (n=406)	41.7 (± 27.71)			
Month 3 (n=392)	42.7 (± 27.73)			
Month 6 (n=364)	42.8 (± 28.15)			
Month 9/ET (n=390)	45.1 (± 29.45)			

## Statistical analyses

No statistical analyses for this end point

### Secondary: Parkinson Anxiety Scale (PAS) Total Score

End point title	Parkinson Anxiety Scale (PAS) Total Score
-----------------	---

End point description:

PAS was 12-item subject or observer rated questionnaire with 3 domains: persistent anxiety measured by 5 questions (Each question ranged from 0 not at all, or never to 4 severe, or nearly always. Best score is 0; worst score is 20.), episodic anxiety measured by 4 questions (Each question ranged from 0 never to 4 nearly always. Best score is 0; worst score is 16. and avoidance anxiety measured by 3

questions (Each question ranges from 0 - never to 4 - nearly always. Best score is 0; worst score is 16). Total score is the sum of the 12 item scores, with a range of 0 to 48; a lower value is desirable. Total score was calculated for the entire questionnaire and each domain. The ITT set included all subjects who were treated with the open-label study drug in the study and have at least one post-baseline clinical utility assessment. Here "N" are the subjects who were evaluable for the outcome measure and "n" signifies subjects who were evaluable for each specified category.

End point type	Secondary
End point timeframe:	
Baseline, Month 3, Month 6 and Month 9	

<b>End point values</b>	IPX203			
Subject group type	Reporting group			
Number of subjects analysed	408			
Units: score on a scale				
arithmetic mean (standard deviation)				
Baseline (n=408)	10.4 (± 8.18)			
Month 3 (n=390)	10.3 (± 8.20)			
Month 6 (n=365)	10.3 (± 7.67)			
Month 9/ET (n=392)	11.1 (± 8.57)			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Non-Motor Symptom Assessment Scale (NMSS) for Parkinson's Disease (PD) Total Score

End point title	Non-Motor Symptom Assessment Scale (NMSS) for Parkinson's Disease (PD) Total Score
-----------------	--

End point description:

The NMSS is a 9 domain (cardiovascular, sleep/fatigue, mood/cognition, perceptual problems, attention/memory, gastrointestinal, urinary, sexual function, and miscellaneous) 30 question scale rating symptom severity on a scale of 0-3 with 3 being most severe; and frequency on a scale of 1-4 with 4 being most frequent. Each question is answered with a severity and frequency rating which are then multiplied. The sum of the products gives the total score. Total scores were calculated for the entire questionnaire and each domain. Zero is the best score and 360 is the worst score. The ITT set included all subjects who were treated with the open-label study drug in the study and have at least one post-baseline clinical utility assessment. Here overall number analyzed "N" are the subjects who were evaluable for the outcome measure and "n" signifies subjects who were evaluable for each specified category.

End point type	Secondary
End point timeframe:	
Baseline, Month 3, Month 6 and Month 9	

End point values	IPX203			
Subject group type	Reporting group			
Number of subjects analysed	407			
Units: score on a scale				
arithmetic mean (standard deviation)				
Baseline (n=407)	32.0 (± 28.95)			
Month 3 (n=388)	32.5 (± 28.49)			
Month 6 (n=362)	33.4 (± 29.19)			
Month 9/ET (n=392)	35.3 (± 30.08)			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Parkinson's Disease Sleep Scale-2 (PDSS-2) Total Score

End point title	Parkinson's Disease Sleep Scale-2 (PDSS-2) Total Score
-----------------	--

End point description:

PDSS-2 was a 15-item self-reported questionnaire. Three domains are defined: disturbed sleep, motor symptoms at night, PD symptoms at night. Total score was calculated for the entire questionnaire and each domain. The PDSS-2 domain scores range from 0 to 20 and the total score is a sum of the 3 domains and ranges from 0 to 60. Higher scores indicate higher frequency and more severe impact of PD on sleep. The ITT set included all subjects who were treated with the open-label study drug in the study and have at least one post-baseline clinical utility assessment. Here overall number analyzed "N" are the subjects who were evaluable for the outcome measure and "n" signifies subjects who were evaluable for each specified category.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Month 3, Month 6 and Month 9

End point values	IPX203			
Subject group type	Reporting group			
Number of subjects analysed	410			
Units: score on a scale				
arithmetic mean (standard deviation)				
Baseline (n=410)	16.6 (± 9.72)			
Month 3 (n=389)	15.8 (± 9.16)			
Month 6 (n=363)	16.1 (± 9.29)			
Month 9/ET (n=387)	16.2 (± 9.28)			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Percentage of Subjects with Treatment Satisfaction Assessment (TSA) Scores 5-7 (Satisfied) versus Scores 1-4 (Dissatisfied or Neutral)

End point title	Percentage of Subjects with Treatment Satisfaction Assessment (TSA) Scores 5-7 (Satisfied) versus Scores 1-4 (Dissatisfied or Neutral)
End point description:	
The TSA was a subject answered assessment rating treatment satisfaction on a scale of 1 to 7; 1 being least satisfied and 7 being most satisfied. The responses were as follows: 1= Very much dissatisfied, 2 = Very dissatisfied, 3 = Somewhat dissatisfied, 4 = Neither satisfied nor dissatisfied, 5 = Somewhat satisfied, 6 = Very satisfied, 7 = Very much satisfied. The ITT set included all subjects who were treated with the open-label study drug in the study and have at least one post-baseline clinical utility assessment. Here overall number analyzed "N" are the subjects who were evaluable for the outcome measure and "n" signifies subjects who were evaluable for each specified category.	
End point type	Secondary
End point timeframe:	
Month 3, Month 6 and Month 9	

End point values	IPX203			
Subject group type	Reporting group			
Number of subjects analysed	392			
Units: percentage of subjects				
number (not applicable)				
Month 3:5-7 (satisfied) (n=392)	80.4			
Month 3:1-4 (dissatisfied or neutral) (n=392)	19.6			
Month 6:5-7 (satisfied) (n=365)	84.4			
Month 6:1-4 (dissatisfied or neutral) (n=365)	15.6			
Month 9/ET:5-7 (satisfied) (n=392)	76.3			
Month 9/ET:1-4 (dissatisfied or neutral) (n=392)	23.7			

## Statistical analyses

No statistical analyses for this end point

## Secondary: TSA Score

End point title	TSA Score
End point description:	
The TSA was a subject answered assessment rating treatment satisfaction on a scale of 1 to 7; 1 being least satisfied and 7 being most satisfied. The responses were as follows: 1= Very much dissatisfied, 2 = Very dissatisfied, 3 = Somewhat dissatisfied, 4 = Neither satisfied nor dissatisfied, 5 = Somewhat satisfied, 6 = Very satisfied, 7 = Very much satisfied. The ITT set included all subjects who were treated with the open-label study drug in the study and have at least one post-baseline clinical utility assessment. Here overall number analyzed "N" are the subjects who were evaluable for the outcome measure and "n" signifies subjects who were evaluable for each specified category.	
End point type	Secondary
End point timeframe:	
Month 3, Month 6 and Month 9	



<b>End point values</b>	IPX203			
Subject group type	Reporting group			
Number of subjects analysed	392			
Units: score on a scale				
arithmetic mean (standard deviation)				
Month 3 (n=392)	5.2 ( $\pm$ 1.25)			
Month 6 (n=365)	5.4 ( $\pm$ 1.19)			
Month 9/ET (n=392)	5.2 ( $\pm$ 1.39)			

### Statistical analyses

No statistical analyses for this end point

### Secondary: Change From Baseline in MDS-UPDRS: Part II Score

End point title	Change From Baseline in MDS-UPDRS: Part II Score
End point description:	
Measure of the MDS-UPDRS - Part II: Motor Aspects of Experiences of Daily Living (M-EDL) was a self-administered questionnaire overall there are 13 questions rated from 0 - normal to 4 severe. Total score ranges from 0 to 52., with a lower score indicating better motor function for daily living and higher score indicating more severe motor symptoms. The ITT included all subjects who were treated with the open-label study drug in the study and have at least one post-baseline clinical utility assessment. Here overall number analyzed "N" are the subjects who were evaluable for the outcome measure and "n" signifies subjects who were evaluable for each specified category.	
End point type	Secondary
End point timeframe:	
Baseline, Month 9	

<b>End point values</b>	IPX203			
Subject group type	Reporting group			
Number of subjects analysed	409			
Units: score on a scale				
arithmetic mean (standard deviation)				
Baseline (n=409)	12.8 ( $\pm$ 7.83)			
Change at Month 9/ET (n=391)	0.9 ( $\pm$ 4.81)			

### Statistical analyses

No statistical analyses for this end point

### Secondary: Change From Baseline in MDS-UPDRS: Part III Score

End point title	Change From Baseline in MDS-UPDRS: Part III Score
End point description:	
Measure of the MDS-UPDRS - Part III: Motor Examination assesses the motor signs of PD; it is completed by the rater. 33 questions rated from 0 - normal to 4 severe. Total score ranges from 0 to 132., with a lower score indicating better motor function and a higher score indicating more severe motor symptoms. The ITT set included all subjects who were treated with the open-label study drug in the study and have at least one post-baseline clinical utility assessment. Here overall number analyzed "N" are the subjects who were evaluable for the outcome measure and "n" signifies subjects who were evaluable for each specified category.	
End point type	Secondary
End point timeframe:	
Baseline, Month 9	

<b>End point values</b>	IPX203			
Subject group type	Reporting group			
Number of subjects analysed	410			
Units: score on a scale				
arithmetic mean (standard deviation)				
Baseline (n=410)	27.5 (± 17.23)			
Change at Month 9/ET (n=392)	0.6 (± 11.29)			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change From Baseline in MDS-UPDRS: Total Score

End point title	Change From Baseline in MDS-UPDRS: Total Score
End point description:	
Measure of MDS-UPDRS - sum total of 4 parts. Part I: Non-Motor Aspects of Experiences of Daily Living (nM-EDL) has 2 components. Component IA contains a number of behaviors assessed by the investigator. Component IB is completed by the subject. Overall, there are 13 questions rated from 0 normal to 4 severe. Total score ranges from 0 to 52. Part II: Motor Aspects of Experiences of Daily Living (M-EDL) self-administered questionnaire. 13 questions rated from 0 normal to 4 severe. Total score ranges from 0 to 52. Part III: Motor Examination assesses the motor signs of PD; completed by the rater. 33 questions rated from 0 normal to 4 severe. Total score ranges from 0 to 132 Part IV: Motor Complications; completed by the rater. 6 questions rated from 0 - normal to 4 severe. Total score ranges from 0 to 24. Overall sum ranges from 0-260. ITT set was used. Here "N" are the subjects who were evaluable for the outcome measure; "n" signifies subjects who were evaluable for each specified category.	
End point type	Secondary
End point timeframe:	
Baseline, Month 9	

<b>End point values</b>	IPX203			
Subject group type	Reporting group			
Number of subjects analysed	409			
Units: score on a scale				
arithmetic mean (standard deviation)				
Baseline (n=409)	56.7 (± 28.64)			
Change at Month 9/ET (n=391)	2.7 (± 16.44)			

## Statistical analyses

No statistical analyses for this end point

### Secondary: Change From Baseline in MDS-UPDRS: Part I Score

End point title	Change From Baseline in MDS-UPDRS: Part I Score
-----------------	---

End point description:

MDS-UPDRS was a multimodal scale assessing impairment and disability. Measure of the MDS-UPDRS - Part I: Non-Motor Aspects of Experiences of Daily Living (nM-EDL) has 2 components. Component IA contains a number of behaviors assessed by the investigator with all pertinent information from the subject and caregivers. Component IB is completed by the subject with or without help from the caregiver but independent of the investigator. Overall there are 13 questions rated from 0 - normal to 4-severe. Total score ranges from 0 to 52, with higher scores reflecting greater severity. The ITT included all subjects who were treated with the open-label study drug in the study and have at least one post-baseline clinical utility assessment. Here overall number analyzed "N" are the subjects who were evaluable for the outcome measure and "n" signifies subjects who were evaluable for each specified category.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Month 9

<b>End point values</b>	IPX203			
Subject group type	Reporting group			
Number of subjects analysed	410			
Units: score on a scale				
arithmetic mean (standard deviation)				
Baseline (n=410)	9.9 (± 6.27)			
Change at Month 9/ET (n=392)	1.2 (± 4.56)			

## Statistical analyses

No statistical analyses for this end point

### Secondary: Change From Baseline in MDS-UPDRS: Sums of Part II and Part III Score

End point title	Change From Baseline in MDS-UPDRS: Sums of Part II and Part III Score
-----------------	---

---

**End point description:**

Sum of MDS-UPDRS Parts II and III. Part II: Motor Aspects of Experiences of Daily Living (M-EDL) self-administered questionnaire. 13 questions rated from 0 - normal to 4 severe. Total score ranges from 0 to 52. Part III: Motor Examination assesses the motor signs of PD; completed by the rater. 33 questions rated from 0 normal to 4 severe. Total score ranges from 0 to 132. Total score ranges from 0 to 184. The ITT set included all subjects who were treated with the open-label study drug in the study and have at least one post-baseline clinical utility assessment. Here overall number analyzed "N" are the subjects who were evaluable for the outcome measure and "n" signifies subjects who were evaluable for each specified category.

---

End point type	Secondary
----------------	-----------

---

End point timeframe:

Baseline, Month 9

---

End point values	IPX203			
Subject group type	Reporting group			
Number of subjects analysed	409			
Units: score on a scale				
arithmetic mean (standard deviation)				
Baseline (n=409)	40.3 (± 23.09)			
Change at Month 9/ET (n=391)	1.5 (± 13.66)			

---

**Statistical analyses**

No statistical analyses for this end point

---

---

**Secondary: Percentage of Subjects With a PGI-S ≥ 4 and PGI-S ≥ 5 Score**

---

End point title	Percentage of Subjects With a PGI-S ≥ 4 and PGI-S ≥ 5 Score
-----------------	---

---

End point description:

The PGI-S was a subject answered assessment rating Parkinson's disease severity on a scale of 1 to 7; 1 being normal not at all ill and 7 extremely severely ill. Higher value indicates increased improvement. The ITT set included all subjects who were treated with the open-label study drug in the study and have at least one post-baseline clinical utility assessment. Here overall number analyzed "N" are the subjects who were evaluable for the outcome measure and "n" signifies subjects who were evaluable for each specified category.

---

End point type	Secondary
----------------	-----------

---

End point timeframe:

Baseline, Month 3, Month 6, and Month 9

---

End point values	IPX203			
Subject group type	Reporting group			
Number of subjects analysed	409			
Units: percentage of subjects				
number (not applicable)				
Baseline: ≥4 (n=409)	64.5			

Baseline: $\geq 5$ (n=409)	20.3			
Month 3: $\geq 4$ (n=390)	66.7			
Month 3: $\geq 5$ (n=390)	20.0			
Month 6: $\geq 4$ (n=363)	62.5			
Month 6: $\geq 5$ (n=363)	20.7			
Month 9/ET: $\geq 4$ (n=393)	65.4			
Month 9/ET: $\geq 5$ (n=393)	22.6			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change From Baseline in MDS-UPDRS: Part IV Score

End point title	Change From Baseline in MDS-UPDRS: Part IV Score
-----------------	--

End point description:

Part 4 of the MDS-UPDRS objectively measures the disability associated with levodopa-induced dyskinesia. Disability was assessed via video analysis by unbiased blinded central raters. Disability was evaluated for communication, drinking from a cup, and ambulation items. 6 questions rated from 0 - normal to 4 severe. Total score ranges from 0 to 24. A higher score indicated more severe symptoms. The ITT set included all subjects who were treated with the open-label study drug in the study and have at least one post-baseline clinical utility assessment. Here overall number analyzed "N" are the subjects who were evaluable for the outcome measure and "n" signifies subjects who were evaluable for each specified category.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Month 9

<b>End point values</b>	IPX203			
Subject group type	Reporting group			
Number of subjects analysed	410			
Units: score on a scale				
arithmetic mean (standard deviation)				
Baseline (n=410)	6.6 ( $\pm$ 2.96)			
Change at Month 9/ET (n=392)	0.0 ( $\pm$ 2.64)			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change From Baseline in PGI-S Score

End point title	Change From Baseline in PGI-S Score
-----------------	-------------------------------------

End point description:

The PGI-S was a subject answered assessment rating Parkinson's disease severity on a scale of 1 to 7; 1 being normal not at all ill and 7 extremely severely ill. Higher value indicates increased improvement. The ITT set included all subjects who were treated with the open-label study drug in the study and have

at least one post-baseline clinical utility assessment. Here overall number analyzed "N" are the subjects who were evaluable for the outcome measure and "n" signifies subjects who were evaluable for each specified category.

End point type	Secondary
End point timeframe:	
Baseline, Month 9	

<b>End point values</b>	IPX203			
Subject group type	Reporting group			
Number of subjects analysed	409			
Units: score on a scale				
arithmetic mean (standard deviation)				
Baseline (n=409)	3.7 (± 1.02)			
Change at Month 9/ET (n=391)	0.0 (± 1.07)			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Percentage of Subjects With a CGI-S ≥ 4 and CGI-S ≥ 5 Score

End point title	Percentage of Subjects With a CGI-S ≥ 4 and CGI-S ≥ 5 Score
-----------------	---

End point description:

The CGI-I was intended as a measure of change in health status. CGI-I scores ranged from 1 (very much improved) through to 7 (very much worse). For the CGI-I, subjects were divided into one of two groups, Responders or Progressors. Responders were scored on a scale of 1-4 which was rated as "no change", "minimally improved", "much improved" or "very much improved." Progressors were scored on a scale of 5-7 which was rated as "minimally worse", "much worse" or "very much worse." The ITT set included all subjects who were treated with the open-label study drug in the study and have at least one post-baseline clinical utility assessment. Here overall number analyzed "N" are the subjects who were evaluable for the outcome measure and "n" signifies subjects who were evaluable for each specified category.

End point type	Secondary
End point timeframe:	
Baseline and Month 9/ET	

<b>End point values</b>	IPX203			
Subject group type	Reporting group			
Number of subjects analysed	409			
Units: percentage of subjects				
number (not applicable)				
Baseline: ≥ 4 (n=409)	66.7			
Baseline: ≥ 5 (n=409)	19.6			
Month 3: ≥ 4 (n=383)	64.8			
Month 3: ≥ 5 (n=383)	18.3			

Month 6: $\geq 4$ (n=358)	61.2			
Month 6: $\geq 5$ (n=358)	14.0			
Month 9/ET: $\geq 4$ (n=392)	65.3			
Month 9/ET: $\geq 5$ (n=392)	17.6			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change From Baseline in CGI-S Score

End point title	Change From Baseline in CGI-S Score
-----------------	-------------------------------------

End point description:

The CGI-I was intended as a measure of change in health status. CGI-I scores ranged from 1 (very much improved) through to 7 (very much worse). For the CGI-I, subjects were divided into one of two groups, Responders or Progressors. Responders were scored on a scale of 1-4 which was rated as "no change", "minimally improved", "much improved" or "very much improved." Progressors were scored on a scale of 5-7 which was rated as "minimally worse", "much worse" or "very much worse." The ITT set included all subjects who were treated with the open-label study drug in the study and have at least one post-baseline clinical utility assessment. Here overall number analyzed "N" are the subjects who were evaluable for the outcome measure and "n" signifies subjects who were evaluable for each specified category. Negative score= not ill.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Month 9

<b>End point values</b>	IPX203			
Subject group type	Reporting group			
Number of subjects analysed	409			
Units: score on a scale				
arithmetic mean (standard deviation)				
Baseline (n=409)	3.8 ( $\pm$ 0.87)			
Change at Month 9/ET (n=390)	0.0 ( $\pm$ 0.81)			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change From Baseline in NMSS for Parkinson's Disease (PD) Total Score

End point title	Change From Baseline in NMSS for Parkinson's Disease (PD) Total Score
-----------------	---

End point description:

The NMSS is a 9 domain (cardiovascular, sleep/fatigue, mood/cognition, perceptual problems, attention/memory, gastrointestinal, urinary, sexual function, and miscellaneous) 30 question scale rating symptom severity on a scale of 0-3 with 3 being most severe; and frequency on a scale of 1-4 with 4 being most frequent. Each question is answered with a severity and frequency rating which are then multiplied. The sum of the products gives the total score. Total scores were calculated for the entire questionnaire and each domain. Zero is the best score and 360 is the worst score. The ITT set

included all subjects who were treated with the open-label study drug in the study and have at least one post-baseline clinical utility assessment. Here overall number analyzed "N" are the subjects who were evaluable for the outcome measure and "n" signifies subjects who were evaluable for each specified category.

End point type	Secondary
End point timeframe:	
Baseline, Month 9	

<b>End point values</b>	IPX203			
Subject group type	Reporting group			
Number of subjects analysed	407			
Units: score on a scale				
arithmetic mean (standard deviation)				
Baseline (n=407)	32.0 (± 28.95)			
Change at Month 9/ET (n=389)	3.8 (± 22.33)			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change From Baseline in PAS: Total Score

End point title	Change From Baseline in PAS: Total Score
End point description:	
<p>PAS was 12-item subject or observer rated questionnaire with 3 domains: persistent anxiety measured by 5 questions (Each question ranged from 0 not at all, or never to 4 severe, or nearly always. Best score is 0; worst score is 20., episodic anxiety measured by 4 questions (Each question ranged from 0 never to 4 nearly always. Best score is 0; worst score is 16. and avoidance anxiety measured by 3 questions (Each question ranges from 0 - never to 4 - nearly always. Best score is 0; worst score is 16). Total score is the sum of the 12 item scores, with a range of 0 to 48; a lower value is desirable. Total score was calculated for the entire questionnaire and each domain. The ITT set included all subjects who were treated with the open-label study drug in the study and have at least one post-baseline clinical utility assessment. Here overall number analyzed "N" are subjects who were evaluable for outcome measure; "n" signifies subjects who were evaluable for each specified category.</p>	
End point type	Secondary
End point timeframe:	
Baseline, Month 9	

<b>End point values</b>	IPX203			
Subject group type	Reporting group			
Number of subjects analysed	408			
Units: score on a scale				
arithmetic mean (standard deviation)				
Baseline (n=408)	10.4 (± 8.18)			
Change at Month 9/ET (n=389)	0.9 (± 6.41)			



## Statistical analyses

No statistical analyses for this end point

### Secondary: Change From Baseline in PDSS-2: Total Score

End point title	Change From Baseline in PDSS-2: Total Score
-----------------	---

End point description:

PDSS-2 was a 15-item self-reported questionnaire. Three domains are defined: disturbed sleep, motor symptoms at night, PD symptoms at night. Total score was calculated for the entire questionnaire and each domain. The PDSS-2 domain scores range from 0 to 20 and the total score is a sum of the 3 domains and ranges from 0 to 60. Higher scores indicate higher frequency and more severe impact of PD on sleep. The ITT set included all subjects who were treated with the open-label study drug in the study and have at least one post-baseline clinical utility assessment. Here overall number analyzed "N" are the subjects who were evaluable for the outcome measure and "n" signifies subjects who were evaluable for each specified category.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Month 9

End point values	IPX203			
Subject group type	Reporting group			
Number of subjects analysed	410			
Units: score on a scale				
arithmetic mean (standard deviation)				
Baseline (n=410)	16.6 (± 9.72)			
Change at Month 9/ET (n=386)	-0.1 (± 8.92)			

## Statistical analyses

No statistical analyses for this end point

### Secondary: Change From Baseline in PDQ-39 Total Score

End point title	Change From Baseline in PDQ-39 Total Score
-----------------	--

End point description:

The PDQ-39 was a disease-specific instrument designed to measure aspects of health that were relevant to subjects with PD, and which may not be included in general health status questionnaires. It evaluated the 8 domains using 39-items of mobility, activities of daily living, emotional well-being, stigma, social support, cognition, communication and bodily discomfort. Total scores was calculated for the entire questionnaire and each domain. The full range of the PDQ-39 Summary Index score is from 0 (no subject-related symptoms/quality of life unaffected) to 100 (highest subject-related symptoms/low quality of life). The ITT set included all subjects who were treated with the open-label study drug in the study and have at least one post-baseline clinical utility assessment. Here overall number analyzed "N" are the subjects who were evaluable for the outcome measure and "n" signifies subjects who were

evaluable for each specified category.

End point type	Secondary
End point timeframe:	
Baseline, Month 9	

<b>End point values</b>	IPX203			
Subject group type	Reporting group			
Number of subjects analysed	406			
Units: score on a scale				
arithmetic mean (standard deviation)				
Baseline (n=406)	41.7 (± 27.71)			
Change at Month 9/ET (n=385)	4.4 (± 18.65)			

### Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

From first dose up to 1 day after last dose (Up to 9 months/Early Termination [ET])

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	22.0
--------------------	------

### Reporting groups

Reporting group title	IPX203
-----------------------	--------

Reporting group description:

IPX203 CD-LD ER capsules, orally in 4 different dose strength (140 mg, 210 mg, 280 mg and 350 mg) as per Investigator's discretion.

Serious adverse events	IPX203		
Total subjects affected by serious adverse events			
subjects affected / exposed	42 / 419 (10.02%)		
number of deaths (all causes)	6		
number of deaths resulting from adverse events	6		
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Lung neoplasm malignant			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
General disorders and administration site conditions			
Chest pain			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Drowning			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	1 / 1		
Asthenia			

subjects affected / exposed	1 / 419 (0.24%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pyrexia			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Non-cardiac chest pain			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Immune system disorders			
Hypersensitivity			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Respiratory, thoracic and mediastinal disorders			
Pulmonary embolism			
subjects affected / exposed	2 / 419 (0.48%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 1		
Aspiration			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Chronic obstructive pulmonary disease			
subjects affected / exposed	2 / 419 (0.48%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 1		
Hypoxia			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Psychiatric disorders			
Confusional state			
subjects affected / exposed	3 / 419 (0.72%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 0		
Psychotic disorder			
subjects affected / exposed	2 / 419 (0.48%)		
occurrences causally related to treatment / all	2 / 2		
deaths causally related to treatment / all	0 / 0		
Hypersexuality			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Delirium			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Depression			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Mental status changes			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Injury, poisoning and procedural complications			
Concussion			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Fall			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Spinal cord injury cervical				
subjects affected / exposed	1 / 419 (0.24%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Femur fracture				
subjects affected / exposed	2 / 419 (0.48%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 0			
Overdose				
subjects affected / exposed	1 / 419 (0.24%)			
occurrences causally related to treatment / all	1 / 1			
deaths causally related to treatment / all	0 / 0			
Head injury				
subjects affected / exposed	1 / 419 (0.24%)			
occurrences causally related to treatment / all	1 / 1			
deaths causally related to treatment / all	0 / 0			
Joint dislocation				
subjects affected / exposed	1 / 419 (0.24%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Cardiac disorders				
Cardiogenic shock				
subjects affected / exposed	1 / 419 (0.24%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 1			
Atrial fibrillation				
subjects affected / exposed	2 / 419 (0.48%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 0			
Acute myocardial infarction				
subjects affected / exposed	1 / 419 (0.24%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Cardiac failure				

subjects affected / exposed	1 / 419 (0.24%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Nervous system disorders			
Cauda equina syndrome			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Polyneuropathy			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Parkinson's disease			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Cerebrovascular accident			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Epilepsy			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Freezing phenomenon			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Peripheral sensory neuropathy			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Syncope			

subjects affected / exposed	2 / 419 (0.48%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Seizure			
subjects affected / exposed	3 / 419 (0.72%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 0		
Subarachnoid haemorrhage			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Ear and labyrinth disorders			
Vertigo			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal disorders			
Colitis			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Vomiting			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Abdominal distension			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		



Volvulus subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	2 / 419 (0.48%) 0 / 2 0 / 1		
Renal and urinary disorders Neurogenic bladder subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 419 (0.24%) 0 / 1 0 / 0		
Nephrolithiasis subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 419 (0.24%) 0 / 1 0 / 0		
Musculoskeletal and connective tissue disorders Lumbar spinal stenosis subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 419 (0.24%) 0 / 1 0 / 0		
Scoliosis subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 419 (0.24%) 0 / 1 0 / 0		
Infections and infestations COVID-19 pneumonia subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 419 (0.24%) 0 / 1 0 / 0		
Herpes zoster subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 419 (0.24%) 0 / 1 0 / 0		
Encephalitis			

subjects affected / exposed	1 / 419 (0.24%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Post procedural infection			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Sepsis			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Pneumonia			
subjects affected / exposed	2 / 419 (0.48%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Gastroenteritis viral			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal infection			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
COVID-19			
subjects affected / exposed	3 / 419 (0.72%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 0		
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Hypokalemia			

subjects affected / exposed	1 / 419 (0.24%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 0 %

<b>Non-serious adverse events</b>	IPX203		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	221 / 419 (52.74%)		
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Lung neoplasm malignant			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Bladder neoplasm			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Vascular disorders			
Hypotension			
subjects affected / exposed	3 / 419 (0.72%)		
occurrences (all)	3		
Hypertensive crisis			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Peripheral venous disease			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Haematoma			
subjects affected / exposed	2 / 419 (0.48%)		
occurrences (all)	2		
Orthostatic hypotension			
subjects affected / exposed	6 / 419 (1.43%)		
occurrences (all)	6		
Hypertension			
subjects affected / exposed	6 / 419 (1.43%)		
occurrences (all)	6		
Deep vein thrombosis			

subjects affected / exposed occurrences (all)	1 / 419 (0.24%) 1		
Surgical and medical procedures			
Knee arthroplasty			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Abscess drainage			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Tooth extraction			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Chest discomfort			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Chills			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Drowning			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Drug ineffective			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Fatigue			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Malaise			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Chest pain			

subjects affected / exposed occurrences (all)	2 / 419 (0.48%) 2		
Oedema peripheral subjects affected / exposed occurrences (all)	5 / 419 (1.19%) 5		
Pyrexia subjects affected / exposed occurrences (all)	4 / 419 (0.95%) 4		
Pain subjects affected / exposed occurrences (all)	3 / 419 (0.72%) 3		
Non-cardiac chest pain subjects affected / exposed occurrences (all)	1 / 419 (0.24%) 1		
Immune system disorders Hypersensitivity subjects affected / exposed occurrences (all)	1 / 419 (0.24%) 1		
Reproductive system and breast disorders Prostatitis subjects affected / exposed occurrences (all)	1 / 419 (0.24%) 1		
Vaginal odour subjects affected / exposed occurrences (all)	1 / 419 (0.24%) 1		
Respiratory, thoracic and mediastinal disorders Sleep apnoea syndrome subjects affected / exposed occurrences (all)	1 / 419 (0.24%) 1		
Pulmonary embolism subjects affected / exposed occurrences (all)	2 / 419 (0.48%) 2		
Chronic obstructive pulmonary disease subjects affected / exposed occurrences (all)	2 / 419 (0.48%) 2		

Cough			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Rhinitis allergic			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Rhinorrhoea			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Dysphonia			
subjects affected / exposed	2 / 419 (0.48%)		
occurrences (all)	2		
Aspiration			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Wheezing			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Pleural effusion			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Bronchospasm			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Asthma			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Dyspnoea			
subjects affected / exposed	2 / 419 (0.48%)		
occurrences (all)	2		
Hypoxia			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Lower respiratory tract congestion			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		

Psychiatric disorders			
Delusion			
subjects affected / exposed	2 / 419 (0.48%)		
occurrences (all)	2		
Compulsions			
subjects affected / exposed	2 / 419 (0.48%)		
occurrences (all)	2		
Anxiety			
subjects affected / exposed	4 / 419 (0.95%)		
occurrences (all)	4		
Affect lability			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Acute psychosis			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Abnormal dreams			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Psychotic disorder			
subjects affected / exposed	3 / 419 (0.72%)		
occurrences (all)	3		
Panic attack			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Depressed mood			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Delirium			
subjects affected / exposed	3 / 419 (0.72%)		
occurrences (all)	3		
Rapid eye movement sleep behaviour disorder			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Rapid eye movements sleep abnormal			

subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Hallucination, visual			
subjects affected / exposed	2 / 419 (0.48%)		
occurrences (all)	2		
Hallucination			
subjects affected / exposed	8 / 419 (1.91%)		
occurrences (all)	8		
Depressive symptom			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Depression			
subjects affected / exposed	7 / 419 (1.67%)		
occurrences (all)	7		
Sleep disorder			
subjects affected / exposed	3 / 419 (0.72%)		
occurrences (all)	3		
Hypersexuality			
subjects affected / exposed	2 / 419 (0.48%)		
occurrences (all)	2		
Confusional state			
subjects affected / exposed	5 / 419 (1.19%)		
occurrences (all)	5		
Obsessive-compulsive personality disorder			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Obsessive-compulsive disorder			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Mental status changes			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Loss of libido			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		



Insomnia			
subjects affected / exposed	6 / 419 (1.43%)		
occurrences (all)	6		
Inappropriate affect			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Suicidal ideation			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Restlessness			
subjects affected / exposed	2 / 419 (0.48%)		
occurrences (all)	2		
Investigations			
Blood alkaline phosphatase increased			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Blood creatine phosphokinase increased			
subjects affected / exposed	3 / 419 (0.72%)		
occurrences (all)	3		
Blood creatinine increased			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Blood bilirubin increased			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Biopsy skin			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Electrocardiogram abnormal			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Blood glucose increased			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Blood potassium increased			

subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Blood urea increased			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Cardiac murmur			
subjects affected / exposed	2 / 419 (0.48%)		
occurrences (all)	2		
Electrocardiogram low voltage			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Electrocardiogram QRS complex prolonged			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Lymphocyte count decreased			
subjects affected / exposed	2 / 419 (0.48%)		
occurrences (all)	2		
Respiratory rate increased			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Red blood cell count decreased			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Neutrophil count increased			
subjects affected / exposed	2 / 419 (0.48%)		
occurrences (all)	2		
Urine uric acid increased			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Weight decreased			
subjects affected / exposed	5 / 419 (1.19%)		
occurrences (all)	5		
White blood cell count increased			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		

Respiratory rate decreased subjects affected / exposed occurrences (all)	1 / 419 (0.24%) 1		
Injury, poisoning and procedural complications			
Concussion subjects affected / exposed occurrences (all)	2 / 419 (0.48%) 2		
Foot fracture subjects affected / exposed occurrences (all)	2 / 419 (0.48%) 2		
Head injury subjects affected / exposed occurrences (all)	1 / 419 (0.24%) 1		
Femur fracture subjects affected / exposed occurrences (all)	1 / 419 (0.24%) 1		
Contusion subjects affected / exposed occurrences (all)	4 / 419 (0.95%) 2		
Fall subjects affected / exposed occurrences (all)	21 / 419 (5.01%) 21		
Overdose subjects affected / exposed occurrences (all)	2 / 419 (0.48%) 2		
Injury subjects affected / exposed occurrences (all)	1 / 419 (0.24%) 1		
Joint dislocation subjects affected / exposed occurrences (all)	2 / 419 (0.48%) 2		
Ligament rupture subjects affected / exposed occurrences (all)	1 / 419 (0.24%) 1		
Muscle strain			

subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Post procedural hypotension			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Skin abrasion			
subjects affected / exposed	2 / 419 (0.48%)		
occurrences (all)	2		
Skin laceration			
subjects affected / exposed	3 / 419 (0.72%)		
occurrences (all)	3		
Spinal column injury			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Facial bones fracture			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Upper limb fracture			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Spinal cord injury cervical			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Procedural pain			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Cardiac disorders			
Aortic valve incompetence			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Tachycardia			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Acute myocardial infarction			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		

Atrioventricular block first degree subjects affected / exposed occurrences (all)	1 / 419 (0.24%) 1		
Cardiac failure subjects affected / exposed occurrences (all)	1 / 419 (0.24%) 1		
Cardiogenic shock subjects affected / exposed occurrences (all)	1 / 419 (0.24%) 1		
Cardiovascular disorder subjects affected / exposed occurrences (all)	1 / 419 (0.24%) 1		
Tachyarrhythmia subjects affected / exposed occurrences (all)	1 / 419 (0.24%) 1		
Atrial fibrillation subjects affected / exposed occurrences (all)	5 / 419 (1.19%) 5		
Bundle branch block left subjects affected / exposed occurrences (all)	1 / 419 (0.24%) 1		
Nervous system disorders			
Tongue biting subjects affected / exposed occurrences (all)	1 / 419 (0.24%) 1		
Bradykinesia subjects affected / exposed occurrences (all)	1 / 419 (0.24%) 1		
Carpal tunnel syndrome subjects affected / exposed occurrences (all)	4 / 419 (0.95%) 4		
Drop attacks subjects affected / exposed occurrences (all)	1 / 419 (0.24%) 1		
Cauda equina syndrome			

subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Cerebrovascular accident			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Cognitive disorder			
subjects affected / exposed	3 / 419 (0.72%)		
occurrences (all)	3		
Dizziness			
subjects affected / exposed	6 / 419 (1.43%)		
occurrences (all)	6		
Memory impairment			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Hypokinesia			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Hypoaesthesia			
subjects affected / exposed	3 / 419 (0.72%)		
occurrences (all)	3		
Hyperkinesia			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Tremor			
subjects affected / exposed	2 / 419 (0.48%)		
occurrences (all)	2		
Orthostatic hypertension			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Taste disorder			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Parkinsonism			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Paraesthesia			

subjects affected / exposed	4 / 419 (0.95%)		
occurrences (all)	4		
Syncope			
subjects affected / exposed	7 / 419 (1.67%)		
occurrences (all)	7		
Dystonia			
subjects affected / exposed	2 / 419 (0.48%)		
occurrences (all)	2		
Sciatica			
subjects affected / exposed	5 / 419 (1.19%)		
occurrences (all)	5		
Seizure			
subjects affected / exposed	3 / 419 (0.72%)		
occurrences (all)	3		
Somnolence			
subjects affected / exposed	3 / 419 (0.72%)		
occurrences (all)	3		
Subarachnoid haemorrhage			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Headache			
subjects affected / exposed	4 / 419 (0.95%)		
occurrences (all)	4		
Motor neurone disease			
subjects affected / exposed	2 / 419 (0.48%)		
occurrences (all)	2		
Nerve compression			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Dysaesthesia			
subjects affected / exposed	2 / 419 (0.48%)		
occurrences (all)	2		
Brachial plexopathy			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Freezing phenomenon			

subjects affected / exposed	2 / 419 (0.48%)		
occurrences (all)	2		
Epilepsy			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Parkinson's disease			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Peripheral sensorimotor neuropathy			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Peripheral sensory neuropathy			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Polyneuropathy			
subjects affected / exposed	3 / 419 (0.72%)		
occurrences (all)	3		
Restless legs syndrome			
subjects affected / exposed	5 / 419 (1.19%)		
occurrences (all)	5		
On and off phenomenon			
subjects affected / exposed	6 / 419 (1.43%)		
occurrences (all)	6		
Neuropathy peripheral			
subjects affected / exposed	2 / 419 (0.48%)		
occurrences (all)	2		
Dyskinesia			
subjects affected / exposed	21 / 419 (5.01%)		
occurrences (all)	21		
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	5 / 419 (1.19%)		
occurrences (all)	5		
Normochromic normocytic anaemia			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		



Microcytic anaemia subjects affected / exposed occurrences (all)	1 / 419 (0.24%) 1		
Lymphadenopathy subjects affected / exposed occurrences (all)	1 / 419 (0.24%) 1		
Ear and labyrinth disorders Vertigo subjects affected / exposed occurrences (all)  Ear disorder subjects affected / exposed occurrences (all)	4 / 419 (0.95%) 4  1 / 419 (0.24%) 1		
Eye disorders Uveitis subjects affected / exposed occurrences (all)  Intraocular haematoma subjects affected / exposed occurrences (all)  Cataract subjects affected / exposed occurrences (all)	1 / 419 (0.24%) 1  1 / 419 (0.24%) 1  4 / 419 (0.95%) 4		
Gastrointestinal disorders Dyspepsia subjects affected / exposed occurrences (all)  Dry mouth subjects affected / exposed occurrences (all)  Volvulus subjects affected / exposed occurrences (all)  Colitis subjects affected / exposed occurrences (all)  Constipation	1 / 419 (0.24%) 1  2 / 419 (0.48%) 2  2 / 419 (0.48%) 2  2 / 419 (0.48%) 2		

subjects affected / exposed	11 / 419 (2.63%)		
occurrences (all)	11		
Dental caries			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Diarrhoea			
subjects affected / exposed	3 / 419 (0.72%)		
occurrences (all)	3		
Abdominal pain upper			
subjects affected / exposed	2 / 419 (0.48%)		
occurrences (all)	2		
Dysphagia			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Gastrooesophageal reflux disease			
subjects affected / exposed	4 / 419 (0.95%)		
occurrences (all)	4		
Hiatus hernia			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Hyperchlorhydria			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Periodontal disease			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Aptyalism			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Abdominal distension			
subjects affected / exposed	2 / 419 (0.48%)		
occurrences (all)	2		
Abdominal discomfort			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Nausea			

subjects affected / exposed occurrences (all)	8 / 419 (1.91%) 8		
Vomiting subjects affected / exposed occurrences (all)	6 / 419 (1.43%) 6		
Food poisoning subjects affected / exposed occurrences (all)	1 / 419 (0.24%) 1		
Hepatobiliary disorders Hepatic cyst subjects affected / exposed occurrences (all)	1 / 419 (0.24%) 1		
Skin and subcutaneous tissue disorders Rash subjects affected / exposed occurrences (all)	5 / 419 (1.19%) 5		
Dermatitis subjects affected / exposed occurrences (all)	1 / 419 (0.24%) 1		
Erythema subjects affected / exposed occurrences (all)	1 / 419 (0.24%) 1		
Pain of skin subjects affected / exposed occurrences (all)	1 / 419 (0.24%) 1		
Pruritus subjects affected / exposed occurrences (all)	2 / 419 (0.48%) 2		
Renal and urinary disorders Incontinence subjects affected / exposed occurrences (all)	1 / 419 (0.24%) 1		
Haematuria subjects affected / exposed occurrences (all)	1 / 419 (0.24%) 1		
Neurogenic bladder			

subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Nephrolithiasis			
subjects affected / exposed	5 / 419 (1.19%)		
occurrences (all)	5		
Micturition urgency			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Ketonuria			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Hypertonic bladder			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Pollakiuria			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Renal cyst			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Urinary incontinence			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Urinary retention			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Ureterolithiasis			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Dysuria			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Chronic kidney disease			
subjects affected / exposed	2 / 419 (0.48%)		
occurrences (all)	2		
Bladder dysfunction			

subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Acute kidney injury			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Urinary tract inflammation			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Endocrine disorders			
Hyperthyroidism			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Musculoskeletal and connective tissue disorders			
Musculoskeletal pain			
subjects affected / exposed	5 / 419 (1.19%)		
occurrences (all)	5		
Muscle spasms			
subjects affected / exposed	4 / 419 (0.95%)		
occurrences (all)	4		
Flank pain			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Bursitis			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Bursa disorder			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Back pain			
subjects affected / exposed	15 / 419 (3.58%)		
occurrences (all)	15		
Arthritis			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Arthralgia			

subjects affected / exposed	4 / 419 (0.95%)		
occurrences (all)	4		
Muscular weakness			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Myopathy			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Scoliosis			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Plantar fasciitis			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Pain in extremity			
subjects affected / exposed	3 / 419 (0.72%)		
occurrences (all)	3		
Osteoarthritis			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Lumbar spinal stenosis			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Neck pain			
subjects affected / exposed	3 / 419 (0.72%)		
occurrences (all)	3		
Tendonitis			
subjects affected / exposed	2 / 419 (0.48%)		
occurrences (all)	2		
Infections and infestations			
Gastritis viral			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Bronchitis			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		

Herpes zoster			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Candida infection			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Cellulitis			
subjects affected / exposed	2 / 419 (0.48%)		
occurrences (all)	2		
COVID-19			
subjects affected / exposed	10 / 419 (2.39%)		
occurrences (all)	10		
COVID-19 pneumonia			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Abscess limb			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Gastroenteritis			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Eye infection bacterial			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Eyelid infection			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Folliculitis			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Cystitis			
subjects affected / exposed	3 / 419 (0.72%)		
occurrences (all)	3		
Gastroenteritis viral			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		

Gastrointestinal infection			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Nasopharyngitis			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Tooth infection			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Pneumonia			
subjects affected / exposed	3 / 419 (0.72%)		
occurrences (all)	3		
Post procedural infection			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Rhinitis			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Sepsis			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Tooth abscess			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Otitis media			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Urinary tract infection			
subjects affected / exposed	21 / 419 (5.01%)		
occurrences (all)	21		
Ear infection viral			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		
Lower respiratory tract infection			
subjects affected / exposed	1 / 419 (0.24%)		
occurrences (all)	1		



Encephalitis subjects affected / exposed occurrences (all)	1 / 419 (0.24%) 1		
Metabolism and nutrition disorders			
Dehydration subjects affected / exposed occurrences (all)	2 / 419 (0.48%) 2		
Fluid retention subjects affected / exposed occurrences (all)	1 / 419 (0.24%) 1		
Gout subjects affected / exposed occurrences (all)	1 / 419 (0.24%) 1		
Hyperglycaemia subjects affected / exposed occurrences (all)	1 / 419 (0.24%) 1		
Hypokalaemia subjects affected / exposed occurrences (all)	2 / 419 (0.48%) 2		
Hyperuricaemia subjects affected / exposed occurrences (all)	1 / 419 (0.24%) 1		
Decreased appetite subjects affected / exposed occurrences (all)	1 / 419 (0.24%) 1		
Vitamin D deficiency subjects affected / exposed occurrences (all)	1 / 419 (0.24%) 1		
Overweight subjects affected / exposed occurrences (all)	1 / 419 (0.24%) 1		

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
22 June 2018	Protocol Amendment 1: Clarified the following text with regard to EMSQ (Appendix N): If you experienced any symptom in the question (Q.1) above on at least one day over the past week, indicate for this symptom (or for these symptoms) the severity to which this symptom impaired your morning activities and social interactions using the severity definitions below. Which of the early morning symptoms (if any) that you identified above and assessed severity in Q.2 above improved after taking a first morning dose of your Parkinson's medication(s)? For each symptom indicate "YES" improved, or "NO" did not improve. If you did not experience the symptom (i.e., answered 0 to Q.1 above), indicate "Did not experience".
26 November 2018	Protocol Amendment 2: Updated measures and/or instruments used in the study to the most current versions available for licensing; Clarified text in Sections 4, 7, 8.1 and Table 2; Updated storage information for consistency; Removed the C-SSRS Baseline/Screening Version. Only the C-SSRS Since Last Visit Version was required for this open-label extension study since subjects were continuing from Study IPX203-B16-02.

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported